戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 s-treated) who received at least one dose of guadecitabine.
2 and identify the recommended phase 2 dose of guadecitabine.
3 l patients who received at least one dose of guadecitabine.
4                            Patients received guadecitabine 30, 45 or 60 mg/m(2)/day subcutaneously on
5                       The treatment included guadecitabine (30 mg/m2) on days 1-4, and pembrolizumab
6                           The combination of guadecitabine 45 mg/m2 with durvalumab 1500 mg was deeme
7 ts were enrolled: 55 (52%) were allocated to guadecitabine 60 mg/m(2) (28 patients were treatment-nai
8                                              Guadecitabine 60 mg/m(2) daily x 5 is the recommended ph
9      We also assigned additional patients to guadecitabine 60 mg/m(2) in a 10-day schedule in a 28-da
10 opulation is ongoing (NCT02348489) to assess guadecitabine 60 mg/m(2) in a 5-day schedule versus stan
11 ter algorithm (for dynamic randomisation) to guadecitabine 60 or 90 mg/m(2) on days 1-5 (5-day schedu
12 hm for dynamic randomisation to subcutaneous guadecitabine 60 or 90 mg/m(2) on days 1-5 of a 28-day t
13                                              Guadecitabine, a next-generation hypomethylating drug, h
14 report the results of a phase Ib/II study of guadecitabine and durvalumab in advanced clear cell rena
15 ive elements, and a mechanistic signature of guadecitabine are associated with response.
16                       We therefore recommend guadecitabine at a dose of 60 mg/m(2) on a 5-day schedul
17  achieved a composite complete response with guadecitabine at all drug doses and schedules investigat
18 vanced melanoma of the hypomethylating agent guadecitabine combined with the anti-CTLA-4 antibody ipi
19 ive was to assess safety and tolerability of guadecitabine, determine the maximum tolerated and biolo
20 n was used in which we treated patients with guadecitabine doses of 3-125 mg/m(2) in separate dose-es
21 domly assigned (1:1) to receive subcutaneous guadecitabine, either once-daily for 5 consecutive days
22       A phase 1 study established 60 mg/m(2) guadecitabine for 5 days as an effective treatment sched
23                                              Guadecitabine given subcutaneously at 60 mg/m(2) daily x
24  used priming with the hypomethylating agent guadecitabine in a phase II study.MethodsEligible patien
25 , randomised, open-label, phase 1/2 study of guadecitabine in cohorts of patients with treatment-naiv
26 pare the activity and safety of two doses of guadecitabine in hypomethylating agent treatment-naive o
27 y and activity of two doses and schedules of guadecitabine in older (>/=65 years) patients with treat
28 nd clinical activity of subcutaneously given guadecitabine in patients with acute myeloid leukaemia o
29                                              Guadecitabine is a next-generation hypomethylating agent
30 tin plus the DNA methyltransferase inhibitor guadecitabine or a standard-of-care chemotherapy regimen
31                              The recommended guadecitabine regimen for this population is 60 mg/m(2)
32                                              Guadecitabine (SGI-110) is a novel hypomethylating dinuc
33                            Patients received guadecitabine (starting at 60 mg/m(2) subcutaneously on
34                                              Guadecitabine was clinically active with acceptable tole
35 rs that were hypomethylated significantly by guadecitabine, with 1,659 genes differentially expressed